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New onset diabetes in a patient with active tuberculosis
Nowo rozpoznana cukrzyca u chorego na gruźlicę płuc
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Abstract
The present report describes the coincidence of pulmonary tuberculosis (TB) and metabolic disorder such as diabetes.
A patient’s bronchoalveolar lavage was found to be positive for acid-fast bacilli (AFB) with following growth of Mycobacte-
rium tuberculosis and complete sensitivity to first line anti-TB drugs. At the same time, the patient presented with typical
diabetes manifestation and subsequently required insulin therapy. Combined treatment resulted in significant clinical im-
provement and gradual resolution of both TB and diabetes symptoms. Therefore, we would like to highlight the value of
appropriate medical management of these disorders sharing at least some clinical symptoms and signs such as weight loss
and fatigue. Moreover, a growing body of evidence indicates that diabetes may play a role as a risk factor for TB.
Consequently, the increasing diabetes prevalence may be a danger to TB control.
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Streszczenie
Opisywany przypadek jest przykładem współistnienia choroby zakaźnej jaką jest gruźlica płuc oraz schorzenia o podłożu
metabolicznym — cukrzycy. U pacjenta wykryto prątki kwasooporne w badaniu bezpośrednim popłuczyn oskrzelowych.
W dalszej diagnostyce zidentyfikowano prątki gruźlicze, potwierdzono pełną lekowrażliwość na podstawowe leki przeciw-
gruźlicze. Jednocześnie u pacjenta zdiagnozowano cukrzycę na podstawie typowych objawów oraz wyników badań labora-
toryjnych, następnie zastosowano leczenie insuliną uzyskując ustąpienie dolegliwości i poprawę wartości glikemii. Naszym
celem jest zwrócenie uwagi na dużą wagę prawidłowego postępowania klinicznego w diagnozowaniu i leczeniu tych dwóch
schorzeń o różnej patofizjologii ale zbliżonych niektórych objawach. Związek pomiędzy tymi dwoma jednostkami chorobowy-
mi jest obecnie bardzo dobrze udokumentowany. Co więcej cukrzyca jest traktowana jako czynnik ryzyka rozwoju gruźlicy
płuc. Ponadto, wzrastająca globalnie liczba przypadków cukrzycy może utrudnić kontrolę zachorowań na gruźlicę płuc.
Słowa kluczowe: gruźlica płuc, wyrównanie metaboliczne, cukrzyca
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Case report
There is firm evidence that diabetes is asso-
ciated with premature death due to various cau-
ses ranging from several cancers and vascular di-
seases to infections, including pneumonia [1]. Ap-
parently, the incidence of pulmonary tuberculosis
is reported to be elevated among diabetic patients
[2]. Thus, we would like to report a case of simul-
taneous development of diabetes and pulmonary
tuberculosis.
In June 2010, a 55-year-old, lean (BMI 27) and
normotensive man was admitted to the respirato-
ry ward in Wielkopolska Centre of Pulmonology
and Thoracic Surgery in Poznań with a month-long
history of dry cough, weight loss, fever with a su-
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(DST) proved the sensitivity to the first-line drugs.
At the same time, the patient was diagnosed with
diabetes, fulfilling both the clinical and laborato-
ry criteria (symptoms and random glucose more
than 11 mmol/l). The initial blood value of glucose
was over 20 mmol/l without the presence ketones in
urine. Glycated haemoglobin (HbA1c levels) was
consequently 9.1%. In addition, cholesterol le-
vels were elevated as well, e.g. total cholesterol
6.4 mmol/l, HDL 1.5 mmol/l, and LDL 4.1 mmol/l.
From the beginning the patient had been treated
with an insulin regimen. After two months of
extensive antituberculous therapy with four drugs
(HRZE) the patient was discharged and treated as
an outpatient following the continuation phase for
the next four months. Subsequent chest radiogra-
phy showed moderate improvement. No sputum
samples to evaluate the culture conversion with
treatment were collected due to the complete re-
solution of the cough. Bronchoscopy was not car-
ried out either.
Discussion
The patient is an example of a common chal-
lenge in our clinical practice referring to bizarre
constellation of symptoms, which could be attri-
buted at least in some part to either diabetes or
tuberculosis. What is more, an acute infection often
appears to be a trigger factor for type 2 diabetes.
spicion of TB or pulmonary abscess. He also repor-
ted osmotic symptoms such as excessive thirst
and polyuria. His previous medical history was
so far unremarkable. His son and mother-in-law
had been treated for pulmonary tuberculosis
a few years before. As an outpatient he received
a course of clarithromycin for supposed commu-
nity-acquired pneumonia without evident impro-
vement. His chest X-ray showed large heterogene-
ous infiltration with presumed multiple cavities in
the right upper lobe as well as moderate infiltra-
tions in the middle- and lower-zone of the left lung.
Subsequently, in order to obtain more precise ima-
ging of the chest and to confirm typical TB abnor-
malities, computer tomography of the chest was
ordered. It showed consolidation, cavities of vario-
us sizes in both upper lobes, and multiple small
nodules in the right upper lobe — tree-in-bud ap-
pearance (Fig. 1, 2). The inflammatory markers
were raised (ESR 75 mm/hour, CRP 68 mg/l). Due
to non-productive cough no sputum sample was
collected. Therefore, the patient underwent a bron-
choscopy, and bronchoalveolar lavage (BAL) fluid
was obtained. The smear was found to be positive
(+++) for acid-fast bacilli. The patient was treated
with the standard regimen consisting of rifampi-
cin (R), isoniazid (H), ethambutol (E), and pyrazi-
namide (Z). The culture became positive after
8 days and subsequently Mycobacterium tubercu-
losis was identified. Drug susceptibility testing
Figure 1. Large cavity with air-fluid level with surrounding consoli-
dation in right upper lobe
Rycina 1. Duża jama z poziomem płynu oraz zagęszczenia w pra-
wym górnym płacie
Figure 2. Consolidation in right upper lobe with bronchial involve-
ment, medium sized cavity in the left upper lobe and multiple nodules
Rycina 2. Zagęszczenia w prawym górnym płacie z zajęciem oskrze-
li, średniej wielkości jama w lewym górnym płacie oraz zmiany
guzkowe
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Making a correct diagnosis such as pulmonary tu-
berculosis in a diabetic patient can be crucial for
the appropriate management.
It is acknowledged that diabetes is increasin-
gly common worldwide. However, it has been re-
ported that the incidence of TB has been declining
since 2006 [3]. Nonetheless, the prevalence of both
conditions varies significantly between ethnic gro-
ups. In the UK, the highest number of diabetics was
observed among the black and south Asian popula-
tion [4]. Of interest, the highest estimated number of
tuberculosis attributable to diabetes was also found
in Asian men and women [5]. In Poland, the inci-
dence of tuberculosis is low (in 2010, 19.7 cases per
100 000 population) and has been gradually decre-
asing for the last 5 years [6]. With respect to diabe-
tes, the number of diabetic patients is estimated at
2 million, the majority of these being type 2 diabetes.
The intriguing association between diabetes
and tuberculosis has been recognized for a long
time. In fact, large trials provide clear data that dia-
betes raises the risk of tuberculosis from moderate
to high. According to recent meta-analysis, diabe-
tic patients are 3.1 times (95% CI 2.27–4.26) more
likely to develop tuberculosis [7]. As a consequen-
ce of this association, there are data to indicate that
unsatisfactory diabetic control further elevates that
risk. Namely, insulin dependence as a marker for
severity of diabetes predicted an increase in that risk
[8, 9]. Our patient presented with poor metabolic
control with insulin therapy from the onset of the
disease as well as with high glycated haemoglobin
(HbA1c 9.1%). On the other hand, surprisingly it has
been found that populous countries such as India,
Peru, and the Russian Federation, with considera-
ble tuberculosis burden, have noticed a rapid incre-
ase in diabetes prevalence [10]. Unfortunately, the-
re are very scarce data on the prevalence of diabe-
tes in other high TB burden countries such as sub-
Saharan Africa [11]. However, it was reported that
in Tanzania, the prevalence of diabetes among ho-
spitalized TB patients was much higher compared
to a control community group (6.5% vs. 0.9%) [12].
Likewise, in another more recent study from Tan-
zania a higher rate of diabetes was found in cultu-
re-confirmed TB compared to a control group (16.7%
vs. 9.4%) [13]. Although such findings do not indi-
cate a direct causal relationship, it further streng-
thens the opinion that in view of the increase in
diabetes we may anticipate a rise in TB as well.
However, in countries with low TB-prevalence, such
as Denmark, the TB risk related to diabetes has been
found to be much lower than expected [14]. More-
over, there is no evidence for the association betwe-
en the glycaemic control and TB in that study.
Although the precise mechanisms leading to
tuberculosis in diabetic patients are not fully cla-
rified, impaired cell-immunity seems to play a pi-
votal role [15]. Decreased phagocyte and T-cell
function as well as vitamin D deficiency are likely
contributors. Moreover, diabetic mice were found
to have significantly lower production of both in-
terferon-g (IFN-g) and interleukin-12 early in the
course of M. tuberculosis infection, showing a di-
minished T helper adaptive immunity. The latter
plays a crucial role in controlling tuberculosis in-
fection [16]. Yet immune dysregulation in diabe-
tes does not affect the sensitivity of IFN-g release
assays (IGRAs) in TB patients [17].
According to some studies diabetic patients
with tuberculosis may present with atypical radio-
graphic features such as lower-lung and multilo-
bar involvement. In one study these patients had
more than twice the chance of having middle- and
lower-zone changes compared with non-diabetic
controls [18]. Thus, it can be quite challenging not
to misdiagnose TB as community-acquired pneu-
monia. Furthermore, the presence of multiple ca-
vities as well as heterogeneous infiltration were
also much more common in diabetic patients [18].
In addition, the duration of therapy was found to
be longer as well as a higher rate of drug resistan-
ce [18]. However, the cure rates were similar betwe-
en the groups. Moreover, diabetes was synchrono-
us with tuberculosis diagnosis in our patient as well
as in over one third of patients in that study [18].
On the other hand, in that study the duration of
diabetes was strongly correlated with TB develop-
ment. In addition, diabetic patients were significan-
tly older (53 vs. 34 years). Among clinical symp-
toms, only a cough was found to be more frequent
in the diabetic group. Of interest, there were no dif-
ferences in the frequency of constitutional symp-
toms such as weight loss and fever between the dia-
betic and non-diabetic TB groups.
The treatment of tuberculosis in diabetic pa-
tients seems to be quite challenging due to a nega-
tive effect of poor metabolic control. Consequen-
tly, these patients are found to have higher rates
of treatment failure and relapse. This may be cau-
sed by the altered pharmacokinetics of anti-TB
drugs in diabetic patients. In one study, in multi-
variate analysis, a higher body weight, the presen-
ce of diabetes, and higher blood glucose contribu-
ted to lower plasma rifampicin concentration [19].
On the other hand, no differences were found in
the oral bioavailability and metabolism of anti-TB
drugs between diabetic patients and controls de-
spite unsatisfactory glycaemic control (HbA1c 11%)
[20]. Therefore, it can be concluded that diabetes
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itself does not affect the pharmacokinetics of anti-
TB medications.
Apparently, diabetic patients seem to have
longer conversion times [21]. In addition, initial
massive cavitation and positive sputum culture
after 2 months of treatment may increase the risk
of failure or relapse and justify longer therapy
of up to 9 months [22]. Although our patient pre-
sented with significant cavitation, his clinical
condition soon improved on treatment. Therefo-
re, we decided to adhere to the standard 6-month
regimen.
Finally, it may be difficult to classify diabetes
in patients with pulmonary TB. Actually, it is usu-
ally assessed as type 2, although in the other stu-
dy the clinical manifestation was closer to type 1
or LADA (late autoimmune diabetes in adults)
spectrum of diabetes with normal BMI (20 kg/m2)
and a mean age of 47 years [20].
In summary, the number of TB cases has been
falling slowly since 2006. Nonetheless, due to the
worldwide rise in diabetes we might expect an in-
crease in the numbers of patients with TB and co-
existing diabetes. In fact, the rising diabetes pre-
valence may be a threat to TB control. Thus, it is
essential to diagnose both these disorders efficien-
tly, bearing in mind that some of their symptoms
are similar. Moreover, according to the guidelines
in patients with pre-existing diabetes, screening for
tuberculosis is highly recommended [23].
The authors would like to thank Prof. Dorota
Zozulińska-Ziółkiewicz (Poznan University of Me-
dical Sciences, Department of Internal Diseases and
Diabetology) for her helpful comments and Dr Be-
ata Nikisch (Wielkopolska Centre of Pulmonology
and Thoracic Surgery, Department of Radiology) for
her assistance in preparing the manuscript.
Conflict of interest
The authors declare no conflict of interest.
References
1. The Emerging Risk Factors Collaboration. Diabetes mellitus,
fasting glucose, and risk of  cause-specific death. N. Engl. J.
Med. 2011; 364: 829–841.
2. Stevenson C., Critchley J., Forouhi N. et al. Diabetes and the
risk of tuberculosis: a neglected threat to public health? Chron-
ic. Illn. 2007; 3: 228–245.
3. WHO Report 2011. Global tuberculosis control report. World
Health Organization 2011, Geneva.
4. Oldroyd J., Banerjee M., Heald A., Cruickshank K. Diabetes and
ethnic minorities. Postgrad. Med. J. 2005; 81: 486–490.
5. Walker C., Unwin N. Estimates of the impact of diabetes on the
incidence of pulmonary tuberculosis in different ethnic groups
in England. Thorax 2010: 65: 578–581.
6. Tuberculosis and lung diseases in Poland 2010. In: Korzeniews-
ka-Koseła M. (ed.). The National Tuberculosis and Lung Dis-
eases Research Institute. Warsaw 2011.
7. Jeon C., Murray M. Diabetes mellitus increases the risk of ac-
tive tuberculosis: a systematic review of 13 observational stud-
ies. PloS. Med. 2008: 5: e152.
8. Dooley K., Chaisson R. Tuberculosis and diabetes mellitus: con-
vergence of two epidemics. Lancet Infect. Dis. 2009; 9: 737–746.
9. Leung C., Lam T., Chan W. et al. Diabetic control and risk of
tuberculosis: a cohort study. Am. J. Epidemiol. 2008; 167: 1486–
–1494.
10. Goldhaber-Fiebert J., Jeon C., Cohen T., Murray M. Diabetes
mellitus and tuberculosis in countries with high tuberculosis
burdens: individual risks and social determinants. Int. J. Epide-
miol. 2011; 40: 417–428.
11. Harries A., Murray M., Jeon C. et al. Defining the research agen-
da to reduce the joint burden of disease from diabetes mellitus
and tuberculosis. Tropical Medicine & International Health
2010; 15: 659–663.
12. Mugusi F., Swai A., Alberti K., McLarty D. Increased preva-
lence of diabetes mellitus in patients with pulmonary tubercu-
losis in Tanzania. Tubercle 1990; 71: 271–276.
13. Faurholt-Jepsen D., Range N., PrayGod G. et al. Diabetes is
a risk factor for pulmonary tuberculosis: a case-control study
from Mwanza, Tanzania. PLoS. Med. 2011; 6: e24215
14. Leegaard A., Riis A., Kornum J. et al. Diabetes, glycemic con-
trol, and risk of tuberculosis. A population-based case-control
study. Diabetes Care 2011; 34: 2530–2535.
15. Zozulińska D., Wierusz-Wysocka B. Hyperglycaemia and in-
flammation are culprits of late complications. Arch. Med. Sci.
2005; 1: 115–118.
16. Martens G., Arikan M., Lee J., Ren F., Greiner D., Kornfeld H.
Tuberculosis susceptibility of diabetic mice. Am. J. Respir. Cell.
Mol. Biol. 2007;37: 518–524.
17. Walsh M., Camerlin A., Miles R. et al. Sensitivity of interferon-g
release assays is not compromised in tuberculosis patients with
diabetes. Int. J. Tuberc. Lung Dis. 2011; 15: 179-184.
18. Tatar D., Senol G., Alptekin S., Karakurum C., Aydin M., Cosk-
unol I. Tuberculosis in diabetics: features in an endemic area.
Jpn. J. Infect. Dis. 2009; 62: 423–427.
19. Nijland H., Ruslami R., Stalenhoef J. et al. Exposure to rifampi-
cin is strongly reduced in patients with tuberculosis and type 2
diabetes. Clin. Infect. Dis. 2006; 43: 848–854.
20. Ruslami R., Nijland H., Adhiarta G. et al. Pharmacokinetics of
antituberculosis drugs in pulmonary tuberculosis patients with
type 2 diabetes. Antimicrob. Agents Chemother. 2010; 54:
1068–1074.
21. Wang C., Yang C., Chen H. et al. Impact of type 2 diabetes on
manifestations and treatment outcome of pulmonary tuberculo-
sis. Epidemiol. Infect. 2009; 137: 203–210.
22. Blumberg H., Burman W., Chaisson R et al. American Thoracic
Society/Centers for Disease Control and Prevention/Infectious
Diseases Society of America: treatment of tuberculosis. Am. J.
Respir. Crit. Care Med. 2003; 167: 603–662.
23. American Thoracic Society/Centers for Disease Control and Pre-
vention/Infectious Diseases Society of America. Controlling tu-
berculosis in the United States. Am. J. Respir. Crit. Care Med.
2005; 172: 1169–1227.
